Potassium ： High Blood Pressure (Hypertension)
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。WHO conditional recommendation. Meta-analysis: systolic -3.49 mmHg. DASH diet (4,700 mg K/day) reduces systolic BP by 8-14 mmHg. Potassium-enriched salt substitutes reduced stroke risk by 14% in a 2022 Lancet study.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'heartcited.com';
const params = 'ingredient\u003Dpotassium\u0026condition\u003Dhigh\u002Dblood\u002Dpressure';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
WHO conditional recommendation. Meta-analysis: systolic -3.49 mmHg. DASH diet (4,700 mg K/day) reduces systolic BP by 8-14 mmHg. Potassium-enriched salt substitutes reduced stroke risk by 14% in a 2022 Lancet study.
Key Study Findings
Case Reports
n=1
Pseudo-Hyperaldosteronism Arising from Licorice Cough Syrup Self-Ingestion: A Case Report.
Dose: Licorice cough syrup (glycyrrhiza glabra)
vs: None
Outcome: Hypokalemia, hypertension, metabolic alkalosis
効果: None
None
対象集団: Single patient with licorice intoxication
Case Reports
13.0 weeks
A case report of Gitelman syndrome in children.
Dose: 3 g
vs: None
Outcome: pain reduction
効果: None
None
対象集団: Hypokalemia
Case Reports
n=1
Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: 65-year-old woman with primary aldosteronism
Meta-Analysis
n=1258
Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials.
Dose: 25 mg/day (typical)
vs: Placebo or standard care
Outcome: All-cause mortality
効果: RR=0.42, P<0.0001
P<0.0001
対象集団: Dialysis-dependent ESRD patients
Case Reports
n=1
Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Patient with refractory primary aldosteronism
Other
8 weeks
Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative …
Dose: 150 g
vs: None
Outcome: whether the rats were acidotic, blood pH was …
効果: None
None
対象集団: None
Key Statistics
22
研究数
1600
参加者数
↑
Positive
B
グレード
Referenced Papers
Pseudo-Hyperaldosteronism Arising from Licorice Cough Syrup Self-Ingestion: A Case Report.
Case Report
Reports (MDPI)
2024
1 件の引用
A case report of Gitelman syndrome in children.
Case Report
Medicine
2023
Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials.
Systematic Review
Frontiers in medicine
2022
9 件の引用
Annals of palliative …
2022
6 件の引用
Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia.
Case Report
Cureus
2022
1 件の引用
Antioxidants (Basel, Switzerland)
2020
10 件の引用
Clinical transplantation
2020
4 件の引用
American family physician
2019
49 件の引用
Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).
Observational
Clinical toxicology (Philadelphia, …
2016
25 件の引用
Acta medica Iranica
2016
10 件の引用
Recent patents on …
2012
Pharmacoepidemiology and drug …
2011
26 件の引用
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
Other
Dermatologic clinics
2010
80 件の引用
Journal of internal …
2005
197 件の引用
American journal of …
2001
51 件の引用
Heart disease and …
1994
European journal of …
1986
22 件の引用
European heart journal
1985
23 件の引用
Drug intelligence & …
1981
7 件の引用
Canadian Medical Association …
1980
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- supplements:
- Typically 99 mg/dose (FDA limit per unit)
- dashdiettarget:
- 4,700 mg/day
- whorecommendation:
- 3,510 mg/day from food
上限量： No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| Licorice cough syrup (glycyrrhiza glabra) | -- | Negative | 1 |
| 3 g | 13.0 weeks | Mixed | -- |
| None | -- | Mixed | 1 |
| 25 mg/day (typical) | -- | Positive | 1258 |
| None | -- | Mixed | 1 |
| 150 g | 8 weeks | Neutral | -- |
| None | -- | Mixed | -- |
| 20 mg | -- | Positive | -- |
推奨摂取タイミング： With meals to reduce GI irritation; divide supplemental doses throughout the day
Safety & Side Effects
報告されている副作用
- ⚠ Gastrointestinal irritation (nausea, vomiting, diarrhea)
- ⚠ Hyperkalemia risk in patients with renal impairment
- ⚠ Cardiac arrhythmias at excessively high serum levels
既知の相互作用
- ● ACE inhibitors (increased hyperkalemia risk)
- ● ARBs (increased hyperkalemia risk)
- ● Potassium-sparing diuretics (increased hyperkalemia risk)
- ● NSAIDs (may increase potassium retention)
耐容上限摂取量： No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Potassium help with High Blood Pressure (Hypertension)?
Based on 22 studies with 1,600 participants, there is moderate evidence from clinical studies that Potassium may support High Blood Pressure (Hypertension) management. Our evidence grade is B (Good Evidence).
How much Potassium should I take for High Blood Pressure (Hypertension)?
Studies have used various dosages. A commonly studied range is Typically 99 mg/dose (FDA limit per unit). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Potassium?
Reported side effects may include Gastrointestinal irritation (nausea, vomiting, diarrhea), Hyperkalemia risk in patients with renal impairment, Cardiac arrhythmias at excessively high serum levels. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Potassium and High Blood Pressure (Hypertension)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 22 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： High Blood Pressure (Hypertension)
Potassium 他の症状・状態について
References
- [1] Chien-Chun Liao et al.. Reports (MDPI). 2024. Pseudo-Hyperaldosteronism Arising from Licorice Cough Syrup Self-Ingestion: A Case Report. doi:10.3390/reports7040085 PubMed
- [2] Jing Ying et al.. Medicine (Baltimore). 2023. A case report of Gitelman syndrome in children. doi:10.1097/MD.0000000000033509 PubMed
- [3] Jing Liu et al.. Front Med (Lausanne). 2022. Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials. doi:10.3389/fmed.2022.828189 PubMed
- [4] Rongfeng Han et al.. Ann Palliat Med. 2022. Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review. doi:10.21037/apm-21-3010 PubMed
- [5] Luis Marín-Martínez et al.. Cureus. 2022. Bilateral Adrenalectomy in a Patient With Refractory Primary Aldosteronism Due to Adrenal Hyperplasia. doi:10.7759/cureus.24267 PubMed
- [6] Dinesh Aryal et al.. Antioxidants (Basel). 2020. Chronic Metabolic Acidosis Elicits Hypertension via Upregulation of Intrarenal Angiotensin II and Induction of Oxidative Stress. doi:10.3390/antiox10010002 PubMed
- [7] Neetika Garg et al.. Clin Transplant. 2020. Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A cross-sectional study. doi:10.1111/ctr.13999 PubMed
- [8] Mary Carpenter et al.. Am Fam Physician. 2019. Clinically Relevant Drug-Drug Interactions in Primary Care. PubMed
- [9] Betty S Chan et al.. Clin Toxicol (Phila). 2016. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). doi:10.1080/15563650.2016.1175620 PubMed
- [10] Sedighe Moradi et al.. Acta Med Iran. 2016. A Woman with Normotensive Primary Hyperaldosteronism. PubMed
- [11] Alfredo Rossi et al.. Recent Pat Inflamm Allergy Drug Discov. 2012. Minoxidil use in dermatology, side effects and recent patents. doi:10.2174/187221312800166859 PubMed
- [12] Pernelle Noize et al.. Pharmacoepidemiol Drug Saf. 2011. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. doi:10.1002/pds.2128 PubMed
- [13] Deepani Rathnayake et al.. Dermatol Clin. 2010. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. doi:10.1016/j.det.2010.03.011 PubMed
- [14] Y Jammes et al.. J Intern Med. 2005. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. doi:10.1111/j.1365-2796.2005.01452.x PubMed
- [15] T Rickman et al.. Am J Kidney Dis. 2001. Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. doi:10.1016/s0272-6386(01)80134-7 PubMed
- [16] E Bourke et al.. Heart Dis Stroke. 1994. Prevention of hypokalemia caused by diuretics. PubMed
- [17] T Dyckner et al.. Eur J Clin Pharmacol. 1986. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial … doi:10.1007/BF00542411 PubMed
- [18] D L Kuchar et al.. Eur Heart J. 1985. High dose furosemide in refractory cardiac failure. doi:10.1093/oxfordjournals.eurheartj.a061793 PubMed
- [19] H L Macfie et al.. Drug Intell Clin Pharm. 1981. New drug evaluations amiloride (Midamor, Merck, Sharp and Dohme). doi:10.1177/106002808101500202 PubMed
- [20] G Lemieux et al.. Can Med Assoc J. 1980. Hypokalemia during the treatment of arterial hypertension with diuretics. PubMed
- [21] G Nuki et al.. Ann Rheum Dis. 1975. Potassium metabolism in patients with rheumatoid arthritis. Effects of treatment with depot tetracosactrin, spironolactone, and oral supplements of potassium chloride. doi:10.1136/ard.34.6.506 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。